Erratum: Pirfenidone for idiopathic pulmonary fibrosis: A systematic review and meta-analysis (PLoS ONE 10:8 (e0136160) 10.1371/journal.pone.0136160);Pirfenidone for idiopathic pulmonary fibrosis: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Aravena, Carlos ^a   Labarca, Gonzalo ^a   Venegas, Carmen ^a   Arenas, Alex ^a   Rada, Gabriel ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Chile   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASTHENIA; CLINICAL EFFECTIVENESS; DECREASED APPETITE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DYSPEPSIA; EXERCISE TEST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION TEST; META ANALYSIS; MORTALITY; NAUSEA; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; IDIOPATHIC PULMONARY FIBROSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PYRIDONES;

EID: 84943237827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140288     Document Type: Erratum

References (32)

1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174: 810-816. PMID: 16809633
2. Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR, et al. (1998) Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 158: 220-225. PMID: 9655733
3. Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King Jr. T.E., Lasky JA, et al. (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366: 1968-1977. doi: 10.1056/NEJMoa1113354 PMID: 22607134
4. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R (2002) Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446: 167-176. PMID: 12098599
5. Misra HP, Rabideau C (2000) Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204: 119-126. PMID: 10718632
6. Kaneko M, Inoue H, Nakazawa R, Azuma N, Suzuki M, et al. (1998) Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 113: 72-76. PMID: 9697986
7. Lee BS, Margolin SB, Nowak RA (1998) Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 83: 219-223. PMID: 9435445
8. Iyer SN, Margolin SB, Hyde DM, Giri SN (1998) Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 24: 119-132. PMID: 9457473
9. Raghu G, Johnson WC, Lockhart D, Mageto Y (1999) Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159: 1061-1069. PMID: 10194146
10. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, et al. (2002) Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41: 1118-1123. PMID: 12521199
11. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, et al. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760-1769. doi: 10.1016/S0140-6736(11)60405-4 PMID: 21571362
12. nice.org.uk (2011) Available: http://www.nice.org.uk/guidance/ta282/documents/idiopathic-pulmonaryfibrosis-pirfenidone-pre-meeting-briefing2.
13. Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, et al. (2010) Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev: CD003134. doi: 10.1002/14651858.CD003134.pub2 PMID: 20824834
14. Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, et al. (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15: 63. doi: 10.1186/2050-6511-15-63 PMID: 25410822
15. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, et al. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083-2092. doi: 10.1056/NEJMoa1402582 PMID: 24836312
16. fda.gov (2015) Available: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022535s000lbl.pdf.
17. Rada G, Perez D, Capurro D (2013) Epistemonikos: a free, relational, collaborative, multilingual database of health evidence. Stud Health Technol Inform 192: 486-490. PMID: 23920602
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070
19. Shuster JJ (2011) Review: cochrane handbook for systematic reviews for interventions, Version 5.1. 0, published 3/2011. Julian PT Higgins and Sally Green, Editors. Wiley Online Library.
20. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, et al. (2011) Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 12: 143. doi: 10.1186/1465-9921-12-143 PMID: 22035508
21. Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, et al. (2011) The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 12: 93. doi: 10.1186/1465-9921-12-93 PMID: 21756364
22. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, et al. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171: 1040-1047. PMID: 15665326
23. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, et al. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35: 821-829. doi: 10.1183/09031936.00005209 PMID: 19996196
24. Vancheri C, Failla M, Crimi N, Raghu G (2010) Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 35: 496-504. doi: 10.1183/09031936.00077309 PMID: 20190329
25. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, et al. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
26. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, et al. (2005) High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229-2242. PMID: 16306520
27. Idiopathic Pulmonary Fibrosis Clinical Research N, Martinez FJ, de Andrade JA, Anstrom KJ, King Jr. T.E., et al. (2014) Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370: 2093-2101. doi: 10.1056/NEJMoa1401739 PMID: 24836309
28. Antoniou KM, Margaritopoulos GA, Siafakas NM (2013) Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 22: 281-291. doi: 10.1183/09059180.00002113 PMID: 23997056
29. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, et al. (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400-408. doi: 10.1016/j.ejphar.2008.06.046 PMID: 18598692
30. Carter NJ (2011) Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 71: 1721-1732. doi: 10.2165/11207710-000000000-00000 PMID: 21902295
31. Ryerson CJ, Collard HR (2014) Hot off the breath: A big step forward for idiopathic pulmonary fibrosis. Thorax 69: 791-792. doi: 10.1136/thoraxjnl-2014-205892 PMID: 24996636
32. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, et al. (2014) All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 189: 825-831. doi: 10.1164/rccm.201311-1951OC PMID: 24476390